Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Zheshang Bank IPO: Deserves No Premium to Peers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Capital Markets

China Zheshang Bank / Equity Capital Markets

<p>China Zheshang Bank, a Zhejiang Province based joint stock bank, is said to have started pre-marketing and hopes to launch its $1.75bn book soon. In this insight, we worked with Asian bank specialist <a href="https://www.smartkarma.com/profiles/12" target="_blank" data-smartkarma-citation="accounts:12">Daniel Tabbush</a>, to look at the fundamentals and try to answer the following questions:</p><ul><li>What should you know about the company?</li><li>What should you know about the deal?</li><li>What are the key risks?</li><li>Where is its fair value?</li><li>How it fares against its peers in banking metrics?</li></ul>

China Zheshang Bank, a Zhejiang Province based joint stock bank, is said to have started pre-marketing and hopes to launch its $1.75bn book soon. In this insight, we worked with Asian bank specialist Daniel Tabbush, to look at the fundamentals and try to answer the following questions:What should you know about the company?What should you know about the deal?What are the key risks?Where is its fair value?How it fares against its peers in banking metrics?

Zheshang Bank IPO Preview: You Have to like Leveraged WMP